The Association of Alopecia Areata-Related Emotional Symptoms with Work Productivity and Daily Activity Among Patients with Alopecia Areata
- PMID: 36484916
- PMCID: PMC9823171
- DOI: 10.1007/s13555-022-00864-1
The Association of Alopecia Areata-Related Emotional Symptoms with Work Productivity and Daily Activity Among Patients with Alopecia Areata
Abstract
Introduction: Patients with alopecia areata (AA) experience psychological and psychosocial symptoms including depression, anxiety, anger, social withdrawal, embarrassment, and low self-esteem. While multiple studies have measured the detrimental emotional impact of AA on patient quality of life, evidence of its effect on work productivity loss (WPL) and daily activities is limited. This study aimed to assess the extent of AA-related emotional symptom (ES) burden on work productivity and activity impairment.
Methods: A cross-sectional survey of dermatologists and their adult patients with AA was conducted in the USA in 2019. Dermatologists provided assessments of patients' clinical characteristics, while patients completed sociodemographic questionnaires along with two validated patient-reported outcome measures of the Work Productivity and Activity Impairment (WPAI) and the AA Patient Priority Outcomes (AAPPO) ES subscale. The WPAI assessed AA-related WPL (employed respondents) and activity impairment (all respondents), and the AAPPO-ES assessed AA-related frequency of feeling self-conscious, embarrassed, sad, or frustrated. Multiple linear regression models were fitted to both WPAI scores with the AAPPO ES as an independent variable.
Results: A total of 242 patients with a mean (SD) age of 39.2 (13.3) years, treated by 59 dermatologists, were evaluated. Mean (SD) ES score was 2.0 (1.1). Mean (SD) work productivity loss [n = 170] and activity impairment [n = 242] were 12.2% (17.4%) and 13.3% (18.3%), respectively. After adjusting for covariates, WPL increased by 4.1% [95% confidence interval (CI) 1.6-6.7%; p = 0.002] and activity impairment increased by 3.1% (95% CI 0.7-5.4%; p = 0.010) for every 1-point increase in ES. For an average patient, a 1-SD decrease (about 1 point) on the ES scale substantially reduced WPL and activity impairment (by at least 25%).
Conclusions: Patients with AA reported significant increases in WPL and activity impairment associated with worsening AA-related ES. These findings underscore the substantial emotional and psychosocial burden among patients with AA and a need for improved treatment options.
Keywords: Activity impairment; Alopecia areata; Alopecia areata patient priority outcomes; Emotional symptoms; Psychodermatology; Work productivity loss.
© 2022. The Author(s).
Figures



Similar articles
-
Patient-Reported Psychosocial Burdens and Quality of Life and Work Productivity Impacts Among Patients with Clinically Distinct Alopecia Areata Severity Profiles.Adv Ther. 2025 Sep;42(9):4556-4570. doi: 10.1007/s12325-025-03302-8. Epub 2025 Jul 21. Adv Ther. 2025. PMID: 40690154 Free PMC article.
-
Health-related quality of life of adult and adolescent patients living with alopecia areata in Australia.Australas J Dermatol. 2024 Aug;65(5):451-461. doi: 10.1111/ajd.14311. Epub 2024 May 20. Australas J Dermatol. 2024. PMID: 38764404
-
Validation of the Alopecia Areata Patient Priority Outcomes (AAPPO) Questionnaire in Adults and Adolescents with Alopecia Areata.Dermatol Ther (Heidelb). 2022 Jan;12(1):149-166. doi: 10.1007/s13555-021-00648-z. Epub 2021 Nov 30. Dermatol Ther (Heidelb). 2022. PMID: 34846634 Free PMC article.
-
Alopecia Areata-Specific Patient-Reported Outcome Measures: A Systematic Review.JAMA Dermatol. 2025 Apr 1;161(4):421-429. doi: 10.1001/jamadermatol.2024.6660. JAMA Dermatol. 2025. PMID: 40042834
-
Psychosocial comorbidities in patients with paediatric alopecia areata: a literature review.Clin Exp Dermatol. 2024 Sep 18;49(10):1118-1124. doi: 10.1093/ced/llae188. Clin Exp Dermatol. 2024. PMID: 38739703
Cited by
-
Awareness, Beliefs, and Psychological Impact of Patients with Alopecia Areata in Saudi Arabia: A Multi-Center Study.Patient Prefer Adherence. 2024 Dec 20;18:2597-2607. doi: 10.2147/PPA.S486039. eCollection 2024. Patient Prefer Adherence. 2024. PMID: 39720634 Free PMC article.
-
Patient-Reported Psychosocial Burdens and Quality of Life and Work Productivity Impacts Among Patients with Clinically Distinct Alopecia Areata Severity Profiles.Adv Ther. 2025 Sep;42(9):4556-4570. doi: 10.1007/s12325-025-03302-8. Epub 2025 Jul 21. Adv Ther. 2025. PMID: 40690154 Free PMC article.
-
Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data.Front Pharmacol. 2024 Aug 13;15:1458438. doi: 10.3389/fphar.2024.1458438. eCollection 2024. Front Pharmacol. 2024. PMID: 39193341 Free PMC article.
-
Exploring Factors That Influence the Measurement of Patient-Reported Impacts of Alopecia Areata.Dermatol Ther (Heidelb). 2025 Jun;15(6):1391-1403. doi: 10.1007/s13555-025-01400-7. Epub 2025 Apr 22. Dermatol Ther (Heidelb). 2025. PMID: 40261547 Free PMC article.
-
Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database.Front Pharmacol. 2025 May 16;16:1497708. doi: 10.3389/fphar.2025.1497708. eCollection 2025. Front Pharmacol. 2025. PMID: 40453668 Free PMC article.
References
LinkOut - more resources
Full Text Sources